Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of breast cancer (BC). Topics covered include expert opinions on: Roche announcing results from the Phase III APHINITY study of Perjeta (pertuzumab) as an adjuvant therapy for BC; Merck & Co. announcing data from the Keytruda (pembrolizumab) I-SPY 2 study; as well as the US approval and launch of Nerlynx (neratinib; Puma Biotechnology).
Business Questions:
• How do KOLs regard Perjeta’s magnitude of benefit in the APHINITY trial?All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved